The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AUTL | -63.94% | -86.12% | -32.62% | -93% |
| S&P | +15.06% | +95.03% | +14.29% | +144% |
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
The biopharmaceutical company announced the pricing of a secondary stock offering.
A private equity firm is taking a $100 million stake in the biotech.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $21.17M | 0.0% |
| Gross Profit | -$5.96M | -214.5% |
| Gross Margin | -28.15% | 0.0% |
| Market Cap | $606.80M | -34.5% |
| Market Cap / Employee | $0.94M | 0.0% |
| Employees | 647 | 39.7% |
| Net Income | -$48.48M | 16.8% |
| EBITDA | -$59.55M | -5.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $125.33M | -82.3% |
| Accounts Receivable | $26.64M | 0.0% |
| Inventory | 23.9 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $305.89M | 7.5% |
| Short Term Debt | $9.28M | 119.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.97% | 6.9% |
| Return On Invested Capital | -44.96% | 2.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$81.47M | -56.9% |
| Operating Free Cash Flow | -$74.06M | -45.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.03 | 1.31 | 0.97 | 1.64 | -22.95% |
| Price to Sales | 88.19 | 95.72 | 45.78 | 20.11 | -85.11% |
| Price to Tangible Book Value | 2.03 | 1.31 | 0.99 | 1.69 | 6.39% |
| Enterprise Value to EBITDA | -7.72 | -8.32 | -3.27 | -7.83 | -52.73% |
| Return on Equity | -82.2% | -81.8% | -49.9% | -52.2% | -15.58% |
| Total Debt | $301.17M | $297.23M | $311.15M | $315.17M | 9.17% |
AUTL earnings call for the period ending March 31, 2020.
AUTL earnings call for the period ending December 31, 2019.
AUTL earnings call for the period ending September 30, 2019.
AUTL earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
